FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new ...
A global drug company which pioneered the Covid vaccine has been victim of a cyber attack, Metro can reveal. AstraZeneca was ...
Speaking to German newspaper Handelsblatt, CEO Pascal Soriot said proposed cost-cutting measures in the country’s healthcare ...
Setting the scene for AstraZeneca AstraZeneca (LSE:AZN) is back in focus after recent share price moves, with the stock ...
By Maggie Fick and Bhanvi Satija BARCELONA, April 23 (Reuters) - Europe risks falling further behind the United States and ...
AstraZeneca's CEO warns that Germany might miss out on new drug launches if it continues its plans to limit pharmaceutical spending. Proposed regulations might hinder drug introductions, affecting ...
April 21 (Reuters) - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met the main goal of a late-stage ...
AstraZeneca reported positive Phase III results for tozorakimab in COPD, meeting the primary endpoint with clinically ...
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective ...
AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results